Article Information
History
- September 15, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Robert Konrat, PhDa,b,*,
- Henrietta Papp, MSc,
- Valéria Szijártó, MDd,
- Tanja Gesell, PhDb,
- Gábor Nagy, MDd,
- Mónika Madai, MSc,
- Safia Zeghbibc,
- Anett Kuczmog, PhDc,
- Zsófia Lanszki, MSc,
- Zsuzsanna Helyes, MDe,
- Gábor Kemenesic,
- Ferenc Jakab, PhDc and
- Eszter Nagy, MDb,d,*
- aDepartment of Structural and Computational Biology, Max F. Perutz Laboratories, University of Vienna, Vienna Biocenter Campus 5, A-1030 Vienna, Austria
- bCalyxha Biotechnologies GmbH, Karl-Farkas-Gasse 22, A-1030 Vienna, Austria
- cNational Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- dCEBINA (Central European Biotech Incubator and Accelerator) GmbH, Karl-Farkas-Gasse 22, A-1030 Vienna, Austria
- eDepartment of Pharmacology and Pharmacotherapy, Medical School & Szentágothai Research Center, University of Pécs, Pécs, Hungary
- ↵*corresponding authors: Prof. Robert Konrat, Department of Structural and Computational Biology, Max F. Perutz Laboratories, University of Vienna, Vienna Biocenter Campus 5, A-1030 Vienna, Austria; robert.konrat{at}univie.ac.at; tel: +4321427752202 & Eszter Nagy, CEBINA GmbH, Karl-Farkas-Gasse 22, A-1030 Vienna, Austria; eszter.nagy{at}cebina.eu; tel: +43190922082310
Posted September 15, 2020.
The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro
